Upon binding to the PD-L1 protein, PPL-C disrupts the interaction between PD-1/PD-L1, resulting in an antigen-specific CD8+ T cell response, reactivating CD8+ T cells, and ultimately killing the tumor cells. Here, CD8A is linked to neoplasm.